Correction: Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients

Brian Grindel; Quanlin Li; Rebecca Arnold; John Petros; Majd Zayzafoon; Mark Muldoon; James Stave; Leland W.K. Chung; Mary C. Farach-Carson

doi:10.18632/oncotarget.11976

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Corrections:

Correction: Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients

Brian Grindel, Quanlin Li, Rebecca Arnold, John Petros, Majd Zayzafoon, Mark Muldoon, James Stave, Leland W.K. Chung and Mary C. Farach-Carson _

PDF | How to cite

Oncotarget. 2016; 7:60775-60775. https://doi.org/10.18632/oncotarget.11976

Metrics: PDF 1689 views | ?

Present: Due to an error made during submission of the revised files, acknowledgements were omitted from this manuscript.

Correct: Corrected acknowledgements information is provided below. Authors sincerely apologize for this oversight.

Original article: Oncotarget. 2016;7(9):10433-47. DOI: 10.18632/oncotarget.7197

ACKNOWLEDGMENTS

This team project was supported by the National Institutes of Health/National Cancer Institute grant P01 CA098912. We are indebted to the many members of our team who contributed to the work including especially Drs. Ann-Christine Olsen, Dror Berel, Billie E. Smith, Arek Arkadiusz, Beatrice Knudsen, Dan Harrington and Andre Rogatko. We thank all of the members of the laboratories of the PO1 for many helpful discussions as this work progressed.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 11976

Publication Alerts

Corrections:

Correction: Perlecan/HSPG2 and matrilysin/MMP-7 as indices of tissue invasion: tissue localization and circulating perlecan fragments in a cohort of 288 radical prostatectomy patients